Relmada Therapeutics, Inc. (RLMD) stock
Close on Nov 11, 2026Market cap $472.55MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $472.55M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.29
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$61.93M
- EPS, diluted
- -$0.96
- Book value per share
- $1.84
- Diluted shares
- 112M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $4.27
- Open
- $4.26
- Day's range
- $4.21 – $4.53
- Volume
- 1,504,415
- Average volume (20 days)
- 1,670,682
- Index membership
- Russell 2000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 1.37
- 52-week range
- $2.97 – $8.00
- RSI (14 days)
- 66.2
- Volatility (1 year)
- 93.1%
- Relative volume
- 1.05×
- WACC
- 11.7%
On 2 of our idea lists: Insiders buying the dip, Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | RLMD | S&P 500 | Difference | RLMD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +30.7% | -2.4% | +33.1 pts | ||
| 3 months | -0.9% | -1.2% | +0.3 pts | ||
| Year to date | -8.3% | +12.3% | −20.6 pts | ||
| 1 year | +34.7% | +12.4% | +22.2 pts | ||
| 3 years | +52.8% | +78.8% | −26.1 pts | +15.2% | +21.4% |
| 5 years | -82.7% | +75.2% | −157.9 pts | -29.6% | +11.9% |
| 10 years | +23.1% | +311.1% | −288.0 pts | +2.1% | +15.2% |
Twelve years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Relmada Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Results
About Relmada Therapeutics
Pharmaceutical Preparations
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company that develops pharmaceutical therapies for oncology and central nervous system disorders. The company focuses on two lead development candidates: NDV-01, an intravesical controlled-release combination of gemcitabine and docetaxel for non-muscle-invasive bladder cancer, and sepranolone, a synthetic neurosteroid targeting conditions associated with excessive GABAergic activity, such as Prader-Willi syndrome and Tourette syndrome. Because its drug candidates remain in clinical testing and have not received regulatory approval, the company does not sell commercial products or serve paying customers.
Company profile, executives and historyRelmada Therapeutics stock: common questions
What is Relmada Therapeutics's stock price?
RLMD closed at $4.43 on Nov 11, 2026, up 3.75% on the day. Over the past 52 weeks it traded between $2.97 and $8.00.
What is Relmada Therapeutics's market cap?
Relmada Therapeutics was worth $472.55M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is RLMD's P/E ratio?
Relmada Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.96), so it has no meaningful P/E ratio.
Does Relmada Therapeutics pay a dividend?
No. Relmada Therapeutics has not paid a cash dividend over the last twelve months.
When does Relmada Therapeutics report earnings next?
Relmada Therapeutics is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has RLMD stock performed over the past year?
Including dividends, RLMD returned +34.7% over the past year, against +12.4% for the S&P 500.
How many RLMD shares are sold short?
11M shares were sold short at the latest FINRA report, 10.51% of the float, or 6.4 days of average trading volume.
Who are Relmada Therapeutics's competitors?
Companies most similar to Relmada Therapeutics by business, industry and size include KTTA, NTHI, CMND, NERV, PPBT.
See a number that looks wrong?